دورية أكاديمية

Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands.

التفاصيل البيبلوغرافية
العنوان: Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands.
المؤلفون: Santer, René, Kinner, Martina, Steuerwald, Ulrike, Kjærgaard, Susanne, Skovby, Flemming, Simonsen, Henrik, Shaiu, Wen-Ling, Chen, Yuan-Tsong, Schneppenheim, Reinhard, Schaub, Jürgen
المصدر: European Journal of Human Genetics; May2001, Vol. 9 Issue 5, p388, 4p
مصطلحات موضوعية: MOLECULAR genetics, GLYCOGEN
مصطلحات جغرافية: FAROE Islands
مستخلص: Glycogen storage disease type IIIA (GSD IIIA) is caused by mutations of the amyloglucosidase gene (AGL). For most populations, none of the AGL mutations described to date is particularly frequent. In this paper, we report that six children with GSD IIIa from the Faroe Islands were found to be homozygous for the novel nonsense mutation c.1222C>T (R408X) of the AGL gene. This mutation is easily detected by restriction enzyme digest with NsiI after mismatch PCR. Investigating five intragenic polymorphisms, we could show that this mutation was always associated with the same haplotype. The c.1222C>T mutation could be detected on two chromosomes of another 50 unselected GSD Ilia patients of other European or North American origin which means that this mutation plays a minor role worldwide. From the fact that we are currently aware of a total of 14 GSD IIIA cases in the Faroese population of 45 000, the observed prevalence is 1:3100. While the novel AGL mutation c.1222C>T was not detectable among 198 German newborns, nine out of 272 children from the Faroese neonatal screening program were found to be heterozygous for this mutation. Thus, the calculated prevalence is 1:3600 (95% CI 1:700-1:6400). We conclude that due to a founder effect, the Faroe Islands have the highest prevalence of GSD IIIA world-wide. The detection of the molecular defect has facilitated the diagnosis and has offered the opportunity for prenatal diagnosis in this patient group. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Human Genetics is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:10184813
DOI:10.1038/sj.ejhg.5200632